Company intelligence / Profile preview
Inmagene Biopharmaceuticals
San Diego, CA, USAinmagenebio.com ↗
- Ownership
- Public · IMA
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Inmagene’s lead asset IMG‑007 demonstrated “remarkable efficacy” in a short four-week proof-of-concept study for atopic dermatitis. Final results from the Phase IIa trial are expected Q3 2024. The company’s pipeline includes multiple differentiated candidates targeting immunological/inflammatory diseases using both mAbs and small molecules. IMG‑004 has completed a Phase I MAD study; IMG‑008 entering global Phase I clinical development. Izokibep/IMG‑020 met endpoints in global phase II studies for psoriasis/PsA.
- Therapeutic areas
- DermatologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
HUTCHMED – collaboration/licensing agreement on multiple assets including exclusive worldwide rights to IMG–007 & IMG–004Ornovi Inc. – out-licensee of certain rights.Celexor Bio – partnership formed with Aditum Bio
04
Financials
- Market cap
- $63.1M
- Total revenue
- $0
- Enterprise value
- $-46M
Beyond the preview
Go deeper on Inmagene Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inmagene Biopharmaceuticals.